Group 1 - Veradermics Inc. is seeking to raise up to $213.6 million through an IPO to advance the commercialization of its oral hair restoration medication [1][2] - The company plans to issue 13.4 million shares at a price range of $14 to $16 per share, potentially valuing the company at approximately $534 million [1] - Wellington Management has expressed interest in purchasing up to $30 million worth of shares at the IPO price [1] Group 2 - Founded in 2019, Veradermics is a late-stage clinical biopharmaceutical company developing a non-hormonal treatment for mild to moderate androgenetic alopecia, currently in late-stage clinical trials [2] - Prior to the IPO, Veradermics raised $150 million in a Series C funding round led by SR One, with participation from new investors and existing supporters [2] - The IPO will be led by Jefferies Financial Group, Leerink Partners, Citigroup, and Cantor Fitzgerald, with plans to list on the New York Stock Exchange under the ticker "MANE" [2]

Group 1 - Veradermics Inc. is seeking to raise up to $213.6 million through an IPO to advance the commercialization of its oral hair restoration medication [1][2] - The company plans to issue 13.4 million shares at a price range of $14 to $16 per share, potentially valuing the company at approximately $534 million [1] - Wellington Management has expressed interest in purchasing up to $30 million worth of shares at the IPO price [1] Group 2 - Founded in 2019, Veradermics is a late-stage clinical biopharmaceutical company developing a non-hormonal experimental treatment for mild to moderate androgenetic alopecia [2] - The company previously raised $150 million in a Series C funding round in October, led by SR One, with participation from new investors and existing supporters [2] - The IPO will be led by Jefferies Financial Group, Leerink Partners, Citigroup, and Cantor Fitzgerald, with plans to list on the New York Stock Exchange under the ticker "MANE" [2]